Engel Law PLLC is investigating whether fair value to NuVasive shareholders will result from the proposed sale of NuVasive, Inc. (NASDAQ: NUVA) to Globus Medical for 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive common stock.
The Firm’s investigation concerns:
(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.